3Spine gets FDA exemption for implant trial

The FDA gave an investigational device exemption to spine devicemaker 3Spine.

Advertisement

The exemption will allow 3Spine to study its Motus device in a clinical trial, according to a June 22 news release. The company finished contracting and site initiation at 16 U.S. centers for a prospective study.

Motus is an implant used in the BalancedBack total joint replacement procedure. It is designed to address leg pain, back pain and spinal instability, 3Spine said.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.